Rexaceract
AssetAlso GT-02287
Brain-penetrant allosteric regulator that restores GCase function.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Autophagy
- 6
- Indications
- 2
- Trials
- 1
- Developer
Indications
6Parkinson's disease
Phase 2, Not yet recruiting, NCT07280299, clinicaltrials.gov, 7 Oct 2026
GBA1 Parkinson's disease
Phase 1, gaintherapeutics.com, 10 Oct 2026
Idiopathic Parkinson disease
Phase 1, gaintherapeutics.com, 10 Oct 2026
3 more
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials2
- Evidence for its targets3
- Competitors12
- Aging relevance2
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.